- Home
- JBGS vs OMER Comparison
JBGS vs OMER Comparison
Compare JBGS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | OMER |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.7M | 844.6M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | JBGS | OMER |
|---|---|---|
| Price | $10.53 | $20.08 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $15.00 | ★ $32.50 |
| AVG Volume (30 Days) | 801.0K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $498,598,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ N/A | $26.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.41 | $4.06 |
| 52 Week High | $22.38 | $21.24 |
Technical Indicators
Market Signals| Indicator | JBGS | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 30.51 | 62.23 |
| Support Level | N/A | $18.00 |
| Resistance Level | $11.55 | N/A |
| Average True Range (ATR) | 0.33 | 0.89 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 17.02 | 74.58 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.